



**Pfizer Announces**

# ***Biomarker Testing / Lung Cancer***

***Competitive Grant Program - internal Pfizer review process***

[日本語版はこちらをクリックしてください](#) ↓

Note this RFP is also available in [Japanese](#) for your convenience

## **I. Background**

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

## II. Eligibility

<b>Geographic Scope:</b>	<ul style="list-style-type: none"> <li>Japan</li> </ul>
<b>Applicant Eligibility Criteria</b>	<ul style="list-style-type: none"> <li>The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.</li> <li>If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project.</li> <li>For projects offering continuing education credit, the requesting organization must be accredited.</li> </ul>

## III. Requirements

<b>Date RFP Issued</b>	<ul style="list-style-type: none"> <li>February 15, 2021</li> </ul>
<b>Clinical Area</b>	<ul style="list-style-type: none"> <li>Lung Cancer</li> </ul>
<b>General Area of Interest for this RFP:</b>	<ul style="list-style-type: none"> <li>Projects that will be considered for Pfizer support will focus on medical education programs covering biomarker analysis for lung cancer.</li> </ul> <p>Treatment strategies for non-small cell lung cancer (NSCLC) have been changed dramatically with molecular targeted drugs targeting driver gene mutations which, contributed to prolong the overall survival in NSCLC patients with driver gene mutation positive such as <i>EGFR</i>, <i>ALK</i>, <i>ROS1</i>, <i>BRAF</i>, <i>MET</i><sup>1)</sup> and <i>NTRK</i> with each companion diagnosis.</p> <p>The previous reports suggested currently there are various barriers to be solved for the biomarker testing in Japanese clinical practice such as the spread or improvement accuracy of companion diagnosis including the next generation sequencer, the improvement methods that the efficient usage of the tumor samples<sup>2-3)</sup>.</p> <p>This educational program aims to improve lung cancer biomarker analysis.</p>

	<ol style="list-style-type: none"> <li>1) Kris, M. G, et al. 2014. "Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs" <i>Jama</i>, 311(19): 1998-2006.</li> <li>2) The Committee of the Biomarker Testing in Japan Lung Cancer Society. 2019. "The Guidance of NGS for lung cancer biomarker testing" (<a href="https://www.haigan.gr.jp/uploads/files/NGS%E3%82%AC%E3%82%A4%E3%83%89%E3%83%A9%E3%82%A4%E3%83%B3%20%E7%90%86%E4%BA%8B%E4%BC%9A%E6%89%BF%E8%AA%8D%20-%201.1%281%29.pdf">https://www.haigan.gr.jp/uploads/files/NGS%E3%82%AC%E3%82%A4%E3%83%89%E3%83%A9%E3%82%A4%E3%83%B3%20%E7%90%86%E4%BA%8B%E4%BC%9A%E6%89%BF%E8%AA%8D%20-%201.1%281%29.pdf</a>)</li> <li>3) J. Shimizu et al. 2020. "Biomarker testing for personalized, first-line therapy in advanced non-squamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)" <i>Ther Adv Med Oncol</i>. 2020 Feb 22;12</li> </ol> <p><i>It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.</i></p>
<p><b>Target Audience:</b></p>	<p>Medical oncologists, Respiratory physicians, Thoracic Surgeries, Pathologists, Medical technologists, Pharmacists</p>
<p><b>Expected Approximate Monetary Range of Grant Applications:</b></p>	<ul style="list-style-type: none"> <li>• Individual projects requesting up to 35,00,000 JPY will be considered.</li> </ul>
<p><b>Key Dates:</b></p>	<ul style="list-style-type: none"> <li>• RFP release date: February 15, 2021</li> <li>• Grant Application due date: <del>April 30, 2021</del> <b>Extended Due Date: June 30, 2021</b></li> </ul> <p>Please note the deadline is midnight Eastern Standard Time (e.g. New York, GMT -5).</p> <ul style="list-style-type: none"> <li>• Anticipated Grant Award Notification Date: August 2021</li> <li>• Grants will be distributed following a fully executed agreement.</li> <li>• Anticipated Project Start and End Dates: October 2021 to September 2022</li> </ul>
<p><b>How to Submit:</b></p>	<ul style="list-style-type: none"> <li>• Please go to <a href="http://www.cybergrants.com/pfizer/IME">www.cybergrants.com/pfizer/IME</a> and sign in. First-time users should click "Create your password".</li> <li>• In the application:             <ul style="list-style-type: none"> <li>○ For the question "What type of request are you submitting?" select Response to a Request for Proposal (RFP)</li> <li>○ For the question "Are you replying to a Request for Proposal as part of the Competitive Grant Program?" select Yes</li> <li>○ Select the following Competitive Grant Program Name: "2021</li> </ul> </li> </ul>

	<p style="text-align: center;"><i>ONC L- Biomarker Testing/Lung Cancer</i></p> <ul style="list-style-type: none"> <li>○ Select the following Primary Area of Interest: “<i>Oncology-Lung</i>”</li> <li>• Requirements for submission:             <ul style="list-style-type: none"> <li>Complete all required sections of the online application and upload your project proposal (see Appendix) in the Letter of Request field.</li> </ul> </li> <li>• If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.</li> </ul> <p><b>IMPORTANT:</b> Be advised applications submitted after the due date will not be reviewed by the committee.</p>
<p><b>Questions:</b></p>	<ul style="list-style-type: none"> <li>• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Akihiro Kamina (meg.japan@pfizer.com), with the subject line “Biomarker Testing / Lung Cancer”.</li> </ul>
<p><b>Mechanism by which Applicants will be Notified:</b></p>	<ul style="list-style-type: none"> <li>• All applicants will be notified via email by the dates noted above.</li> <li>• Applicants may be asked for additional clarification during the review period.</li> </ul>

#### IV. Terms and Conditions

Please take note every RFP released by Pfizer Global Medical Grants (GMG) is governed by specific terms and conditions. These terms and conditions can be reviewed [here](#).

## Appendix A Project Description

**Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:**

<b>Goals and Objectives</b>	<ul style="list-style-type: none"> <li>Briefly state the overall goal of the project.</li> <li>List the objectives you plan to meet with your project, in terms of learning and expected outcomes.</li> </ul>
<b>Needs Assessment for the Project</b>	<ul style="list-style-type: none"> <li>Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.</li> </ul>
<b>Target Audience</b>	<ul style="list-style-type: none"> <li>Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.</li> </ul>
<b>Project Design and Methods</b>	<ul style="list-style-type: none"> <li>Describe the planned project, the educational approach, and the way the planned methods address the established need.</li> </ul>
<b>Innovation</b>	<p>Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.</p>
<b>Evaluation and Outcomes</b>	<ul style="list-style-type: none"> <li>In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.</li> </ul>
<b>Dissemination Plan</b>	<ul style="list-style-type: none"> <li>Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.</li> </ul>

<b>Anticipated Project Timeline</b>	<ul style="list-style-type: none"> <li>• Provide an anticipated timeline for your project including project start/end dates.</li> </ul>
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.</li> </ul>
<b>Organization Detail</b>	<ul style="list-style-type: none"> <li>• Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.</li> </ul>
<b>Budget Narrative</b>	<ul style="list-style-type: none"> <li>• Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application</li> <li>• While estimating your budget please keep the following items in mind:             <ul style="list-style-type: none"> <li>○ Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).</li> <li>○ Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.</li> </ul> </li> </ul>